Analyst Update: Aeropostale, Bank of Greece, Pfizer

Analysts adjusted their ratings on Aeropostale Inc (ARO), National Bank of Greece (ADR) (NBG), and Pfizer Inc. (PFE)

Feb 10, 2015 at 12:20 PM
facebook twitter linkedin


Analysts are weighing in today on teen apparel maker Aeropostale Inc (NYSE:ARO), Athens-based financial institution National Bank of Greece (ADR) (NYSE:NBG), and pharmaceutical giant Pfizer Inc. (NYSE:PFE). Here's a quick look at today's brokerage notes on ARO, NBG, and PFE.

.
  • ARO is up over 16% this morning to reach $3.07, following last night's news that the company had better-than-expected quarterly sales. In response, SunTrust Robinson and Topeka Capital both raised their price targets on the equity to $3.50, while underscoring "neutral" and "hold" ratings, respectively. On the charts, Aeropostale Inc is recovering from December's multi-year lows, with the shares advancing roughly 32.3% year-to-date. Meanwhile, sentiment in the stock's options pits is nearing a bullish climax, with ARO's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 32.58 sitting just seven percentage points away from an annual optimistic peak. However, nearly 24% of ARO's available float is sold short, which would take over five sessions to cover at average trading volumes -- suggesting a portion of this call buying could be hedging activity.

  • Hopes for a potential debt compromise between Greece and its international creditors have NBG pointing over 15% higher today to hit $1.29, but the stock has nevertheless been hit with a round of bearish brokerage notes. Specifically, Wood & Company and Barclays both cut their price targets, with the former backing a "buy" prediction and the latter reiterating the stock at "equal weight." Longer term, the shares of National Bank of Greece (ADR) are getting crushed, with the equity -- down about 28% year-to-date --touching an all-time low of $0.98 at the end of January. Not surprisingly, sentiment in NBG's options pits is extremely bearish, with its 50-day ISE/CBOE/PHLX put/call volume ratio of 0.23 ranking higher than 98% of all similar annual readings.

  • News that PFE is buying back $5 billion worth of its stock from Goldman Sachs has the company up 2.7% this morning to reach a 10-year high of $34. In response, J.P. Morgan Securities raised its price target by $1 to $36, while reiterating its "overweight" rating for the stock. The upbeat coverage is supported by Pfizer Inc.'s performance on the charts, as the equity is up over 23% since falling to an annual low of $27.51 in mid-October. Sentiment in PFE's options pits is bullish, with the stock's 10-day ISE/CBOE/PHLX call/put volume ratio of 3.72 sitting in the 62nd percentile of its annual range.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners